Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

GRI

GRI Bio Inc

Apr 15 • 04:00PM ET

0.5299

Dollar change +0.0193
Percentage change 3.79	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-63.58	Insider Own	6.23%	Shs Outstand	3.20M	Perf Week	-2.90%
Market Cap	1.70M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.00M	Perf Month	-31.71%
Income	-13.28M	PEG	-	EPS next Q	-	Inst Own	0.97%	Short Float	1.81%	Perf Quarter	-75.98%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	8.09%	Short Ratio	0.07	Perf Half Y	-94.95%
Book/sh	0.40	P/B	1.32	EPS next Y	-	ROA	-373.75%	Short Interest	0.05M	Perf Year	-99.32%
Cash/sh	0.57	P/C	0.94	EPS next 5Y	-	ROE	-1021.38%	52W Range	0.50 - 115.50	Perf YTD	-80.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	26.64%	ROI	-5128.57%	52W High	-99.54%	Beta	-1.64
Dividend TTM	-	Quick Ratio	1.09	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	5.34%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	1.09	EPS Y/Y TTM	61.85%	Oper. Margin	0.00%	RSI (14)	29.38	Volatility	6.74% 8.43%
Employees	4	Debt/Eq	0.04	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	2520.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	87.41%	Payout	-	Rel Volume	0.03	Prev Close	0.51
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Apr 01 BMO	Avg Volume	741.24K	Price	0.53
SMA20	-19.98%	SMA50	-39.55%	SMA200	-93.99%	Trades		Volume	24,303	Change	3.79%

Apr-08-24 08:35AM	GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference (GlobeNewswire) +5.16%
Apr-01-24 07:35AM	GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-28-24 09:00AM	GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference (GlobeNewswire)
Mar-14-24 08:45AM	GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators (GlobeNewswire)
Mar-04-24 08:30AM	GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom (GlobeNewswire)
08:55AM	Loading…
Feb-02-24 08:55AM	Why Is GRI Bio (GRI) Stock Down 21% Today? (InvestorPlace) -26.15%
08:00AM	GRI Bio Announces Pricing of $5.5 Million Public Offering (GlobeNewswire)
Jan-26-24 08:05AM	GRI Bio Announces Reverse Stock Split (GlobeNewswire) +5.62%
Dec-06-23 01:47PM	GRI Bio begins patent enrollment for Phase 2a study of GRI-0621 for IPF treatment (News Direct) -5.98%
Dec-05-23 09:05AM	GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis ( IPF ) (GlobeNewswire) -25.39%
Nov-27-23 08:35AM	GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT ( iNKT ) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis ( IPF ) (GlobeNewswire) -13.33%
Nov-15-23 08:05AM	GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -6.49%
Oct-31-23 08:45AM	GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases (GlobeNewswire) +5.17%
Oct-19-23 08:45AM	GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference (GlobeNewswire)
Oct-18-23 10:00AM	JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023 (ACCESSWIRE) -5.47%
08:35AM	Loading…
Oct-17-23 08:35AM	GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression (GlobeNewswire) -14.09%
Oct-11-23 09:05AM	GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference (GlobeNewswire)
Oct-05-23 08:45AM	GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions (GlobeNewswire)
Sep-29-23 09:00AM	September Is Pulmonary Fibrosis Awareness Month: Heres What One Company Is Doing To Develop A Treatment For This Deadly Disease (ACCESSWIRE) -6.91%
Sep-06-23 09:05AM	GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Sep-01-23 09:15AM	IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis - Could GRI-0621 Be The Solution? (ACCESSWIRE)
Aug-29-23 11:06AM	GRI Bio Engages B2i Digital to Deploy Cutting-Edge Engagement Campaign (Newsfile) +5.74%
Aug-25-23 09:00AM	GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus (ACCESSWIRE) -12.26%
Aug-23-23 09:00AM	GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR (GlobeNewswire) -25.75%
Aug-16-23 12:00PM	JTC Team Announces the Launch of the Virtual Investor "What This Means" On Demand Video Series (ACCESSWIRE)
Aug-14-23 08:05AM	GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-23 08:35AM	GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models (GlobeNewswire)
Aug-03-23 08:30AM	GRI Bio (NASDAQ: GRI) to Present at Benzingas Virtual Biotech Conference (GlobeNewswire)
Jul-26-23 11:15AM	JTC Team to Host Two Virtual Investor Spotlight Events on Thursday, July 27th (ACCESSWIRE)
Jul-24-23 09:00AM	GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor The GRI Opportunity Spotlight Event (GlobeNewswire)
08:45AM	Loading…
Jul-05-23 08:45AM	GRI Bio, Inc. (NASDAQ: GRI) to Participate in the Virtual Investor Summer Spotlight Series (GlobeNewswire)
Jun-27-23 08:45AM	GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio (GlobeNewswire)
Jun-15-23 08:45AM	GRI Bio (NASDAQ: GRI) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (GlobeNewswire) -7.41%
Jun-13-23 08:35AM	GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and Launch of New Website (GlobeNewswire)
May-22-23 08:45AM	GRI Bio (NASDAQ: GRI) Provides Business Outlook and Highlights Upcoming Milestones for Innovative Pipeline of NKT Cell Modulators (GlobeNewswire)
Apr-27-23 09:05AM	GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event (GlobeNewswire) +17.98%
Apr-25-23 08:45AM	GRI Bio (NASDAQ: GRI) Announces Appointment of Leanne Kelly as Chief Financial Officer (GlobeNewswire) -5.53%

GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GRI

GRI Bio Inc

Upgrade your FINVIZ experience